BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li D, Wang X, von Schaewen M, Tao W, Zhang Y, Heller B, Hrebikova G, Deng Q, Sun Q, Ploss A, Zhong J, Huang Z. Immunization With a Subunit Hepatitis C Virus Vaccine Elicits Pan-Genotypic Neutralizing Antibodies and Intrahepatic T-Cell Responses in Nonhuman Primates. J Infect Dis 2017;215:1824-31. [PMID: 28398489 DOI: 10.1093/infdis/jix180] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Tarr AW, Backx M, Hamed MR, Urbanowicz RA, McClure CP, Brown RJP, Ball JK. Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies. Antiviral Res 2018;160:25-37. [PMID: 30217650 DOI: 10.1016/j.antiviral.2018.09.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Masavuli MG, Wijesundara DK, Underwood A, Christiansen D, Earnest-Silveira L, Bull R, Torresi J, Gowans EJ, Grubor-Bauk B. A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice. Front Immunol. 2019;10:1145. [PMID: 31178869 DOI: 10.3389/fimmu.2019.01145] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
3 Law JLM, Logan M, Wong J, Kundu J, Hockman D, Landi A, Chen C, Crawford K, Wininger M, Johnson J, Mesa Prince C, Dudek E, Mehta N, Tyrrell DL, Houghton M. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine. J Virol 2018;92:e02141-17. [PMID: 29540595 DOI: 10.1128/JVI.02141-17] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
4 Mesalam AA. Hepatitis C Virus Vaccine Development: A Step Forward. J Infect Dis 2021;223:2014-6. [PMID: 33038255 DOI: 10.1093/infdis/jiaa644] [Reference Citation Analysis]
5 Zhu F, Wang Y, Xu Z, Qu H, Zhang H, Niu L, Xue H, Jing D, He H. Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice. Mol Med Rep 2019;19:1016-23. [PMID: 30569131 DOI: 10.3892/mmr.2018.9739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Laidlaw SM, Dustin LB. An HCV Vaccine on the Fly. J Infect Dis 2020;221:1216-8. [PMID: 31074788 DOI: 10.1093/infdis/jiz231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Gomez-Escobar E, Burlaud-Gaillard J, Visdeloup C, Silva ARE, Coutant P, Roingeard P, Beaumont E. Incorporation of apolipoprotein E into HBV-HCV subviral envelope particles to improve the hepatitis vaccine strategy. Sci Rep 2021;11:21856. [PMID: 34750487 DOI: 10.1038/s41598-021-01428-7] [Reference Citation Analysis]
8 Wang X, Yan Y, Gan T, Yang X, Li D, Zhou D, Sun Q, Huang Z, Zhong J. A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey. Gut 2019;68:140-9. [PMID: 29180585 DOI: 10.1136/gutjnl-2017-314870] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
9 Qu P, Zhang W, Li D, Zhang C, Liu Q, Zhang X, Wang X, Dai W, Xu Y, Leng Q, Zhong J, Jin X, Huang Z. Insect cell-produced recombinant protein subunit vaccines protect against Zika virus infection. Antiviral Res 2018;154:97-103. [PMID: 29665376 DOI: 10.1016/j.antiviral.2018.04.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
10 Ramirez S, Bukh J. Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies. Antiviral Res 2018;158:264-87. [PMID: 30059723 DOI: 10.1016/j.antiviral.2018.07.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
11 Tortella GR, Rubilar O, Diez MC, Padrão J, Zille A, Pieretti JC, Seabra AB. Advanced Material Against Human (Including Covid-19) and Plant Viruses: Nanoparticles As a Feasible Strategy. Glob Chall 2020;:2000049. [PMID: 33614127 DOI: 10.1002/gch2.202000049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Zhang S, Sun F, Ren T, Duan Y, Gu H, Lai C, Wang Z, Zhang P, Wang X, Yang P. Immunogenicity of an influenza virus-vectored vaccine carrying the hepatitis C virus protein epitopes in mice. Antiviral Res 2017;145:168-74. [PMID: 28778831 DOI: 10.1016/j.antiviral.2017.07.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Christiansen D, Earnest-Silveira L, Chua B, Boo I, Drummer HE, Grubor-Bauk B, Gowans EJ, Jackson DC, Torresi J. Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 Agonists. Viral Immunol 2018;31:338-43. [PMID: 29489437 DOI: 10.1089/vim.2017.0182] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Prentoe J, Janitzek CM, Velázquez-Moctezuma R, Goksøyr L, Olsen RW, Fanalista M, Augestad EH, Thrane S, Pihl AF, Gottwein JM, Sander AF, Bukh J. Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens. PLoS One 2021;16:e0255336. [PMID: 34329365 DOI: 10.1371/journal.pone.0255336] [Reference Citation Analysis]
15 Van Landuyt L, Lonigro C, Meuris L, Callewaert N. Customized protein glycosylation to improve biopharmaceutical function and targeting. Current Opinion in Biotechnology 2019;60:17-28. [DOI: 10.1016/j.copbio.2018.11.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]